ストックスクリーナーアプリを入手
0.21
1.87%
-0.004
アフターアワーズ：
.23
0.02
+9.52%
前日終値:
$0.214
開ける：
$0.21
24時間の取引高:
1.70M
Relative Volume:
0.84
時価総額：
$8.35M
収益：
-
当期純損益:
$-51.06M
株価収益率:
-0.1522
EPS:
-1.38
ネットキャッシュフロー:
$-40.03M
1週間 パフォーマンス:
+3.60%
1か月 パフォーマンス:
+38.25%
6か月 パフォーマンス:
-63.09%
1年 パフォーマンス:
-52.71%
1日の値動き範囲:
$0.21
$0.2574
1週間の範囲:
$0.1826
$0.2574
52週間の値動き範囲:
$0.1315
$1.31
Viracta Therapeutics Inc Stock (VIRX) Company Profile
VIRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VIRX
Viracta Therapeutics Inc
|
0.21 | 8.35M | 0 | -51.06M | -40.03M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Viracta Therapeutics Inc Stock (VIRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-16 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2022-02-01 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-05-03 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-26 | 開始されました | SVB Leerink | Outperform |
| 2021-03-25 | 開始されました | Evercore ISI | Outperform |
Viracta Therapeutics Inc (VIRX) 最新ニュース
Viracta Therapeutics' SWOT analysis: stock focus narrows amid pipeline shift - Investing.com
Viracta Therapeutics, Inc. (NASDAQ:VIRX) Short Interest Update - Defense World
Viracta Therapeutics Inc (NASDAQ: VIRX) Has Great Upside Potential - Stocks Register
Viracta Therapeutics' SWOT analysis: focused strategy reshapes stock outlook By Investing.com - Investing.com Australia
Epstein-Barr Virus (EBV) Market A Deep Dive into Current - openPR
Viracta Therapeutics' SWOT analysis: focused strategy reshapes stock outlook - Investing.com
Viracta Therapeutics faces Nasdaq delisting over non-compliance By Investing.com - Investing.com Australia
Viracta Therapeutics faces Nasdaq delisting over non-compliance - Investing.com
Viracta Therapeutics faces Nasdaq delisting risk - Investing.com India
Viracta Therapeutics faces Nasdaq delisting risk By Investing.com - Investing.com Canada
Contrasting ALX Oncology (NASDAQ:ALXO) & Viracta Therapeutics (NASDAQ:VIRX) - Defense World
Royal Bank of Canada Cuts Viracta Therapeutics (NASDAQ:VIRX) Price Target to $2.00 - Defense World
VIRX stock touches 52-week low at $0.15 amid market challenges - Investing.com UK
Viracta Therapeutics Highlights Strategic Focus and Financials - TipRanks
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Sunesis: Q3 Earnings Snapshot - mySA
Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Head and Neck Cancer Market Expected to Reach $9.07 Billion by 2030, Growing at 16.2% CAGR As Revealed In N... - WhaTech
Viracta Cuts Workforce 42%, Narrows Focus on PTCL Drug as Cash Runway Tightens - StockTitan
Natural Killer T-Cell Lymphoma Market 2024 Projections, - openPR
Viracta Thera pins hopes on lead lymphoma program - The Pharma Letter
VIRX stock touches 52-week low at $0.18 amid market challenges - Investing.com UK
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma - The Manila Times
Viracta Therapeutics cuts workforce to focus on cancer program - Investing.com
Viracta Therapeutics cuts workforce to focus on cancer program By Investing.com - Investing.com Canada
Viracta Therapeutics Announces Reprioritization of - GlobeNewswire
Viracta (VIRX) Cuts 42% of Workforce, Restructures Board Amid Strategic Shift | VIRX Stock News - StockTitan
Pharma takes aim at a wily foe — the Epstein-Barr virus - Yahoo Finance
T-cell Lymphoma Market Segments Analysis Report 2024-2031 - InsightAce Analytic
Advanced Gastric Carcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Peripheral T-Cell Lymphoma Market Expected to Experience Major - openPR
Head and Neck Cancer Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic
Natural Killer T-Cell Lymphoma Market Trends and Growth - openPR
Viracta Therapeutics' SWOT analysis: narrowed focus shapes stock outlook By Investing.com - Investing.com South Africa
Viracta Therapeutics' SWOT analysis: narrowed focus shapes stock outlook - Investing.com India
Head and Neck Cancer Market to Reach $9.07 Billion by 2030, Growing at 16.2% CAGR - WhaTech
Ionis Pharmaceuticals announces $500 million public offering | Biotechnology | The Pharmaletter - The Pharma Letter
The Psychology of Viracta Therapeutics Inc Inc. (VIRX) Price Performance: Understanding Market Sentiment - The InvestChronicle
Viracta Therapeutics Inc (VIRX) Stock: Navigating a Year of Volatility - The InvestChronicle
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Are Smart Investors Making the Right Decision? Viracta Therapeutics Inc (VIRX) - SETE News
Ratio Review: Analyzing Viracta Therapeutics Inc (VIRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
What is the investor’s view on Viracta Therapeutics Inc (VIRX)? - US Post News
Viracta Therapeutics Inc (VIRX) can make a big difference with a little luck - SETE News
Viracta Therapeutics Inc (VIRX)’s stock decline to 0.22 per share - US Post News
Ratio Analysis: Unpacking Viracta Therapeutics Inc (VIRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Viracta Therapeutics stock hits 52-week low at $0.27 - Investing.com
Viracta Therapeutics Inc (VIRX) 財務データ
収益
当期純利益
現金流量
EPS
Viracta Therapeutics Inc (VIRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Pomerantz Roger | Director |
Nov 25 '24 |
Option Exercise |
0.00 |
9,034 |
0 |
126,478 |
| ROYSTON IVOR | Director |
Aug 25 '24 |
Option Exercise |
0.00 |
25,219 |
0 |
814,522 |
| Pomerantz Roger | Director |
Aug 25 '24 |
Option Exercise |
0.00 |
9,034 |
0 |
117,444 |
| Pomerantz Roger | Director |
May 25 '24 |
Option Exercise |
0.00 |
9,035 |
0 |
108,410 |
| ROYSTON IVOR | Director |
May 25 '24 |
Option Exercise |
0.00 |
25,219 |
0 |
789,303 |
| ROYSTON IVOR | Director |
Feb 25 '24 |
Option Exercise |
0.00 |
25,219 |
0 |
764,084 |
| Pomerantz Roger | Director |
Feb 25 '24 |
Option Exercise |
0.00 |
9,034 |
0 |
99,375 |
| Chevallard Daniel R. | CFO and COO |
Feb 25 '24 |
Option Exercise |
0.00 |
6,889 |
0 |
105,711 |
| Chevallard Daniel R. | CFO and COO |
Feb 27 '24 |
Sale |
0.73 |
3,405 |
2,493 |
102,306 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):